Gema Ariceta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gema Ariceta has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Alfredo Vallo
Nefrología Pediátrica, Hospital de Cruces, Facultad de Medicina, Universidad del País Vasco, Baracaldo, Vizcaya, España
3 shared publications- Ramon (Vilalta Casas) Vilalta
Nefrología Pediátrica, Hospital Vall d'Hebrón, Barcelona, Spain
2 shared publications Víctor García Nieto
Nefrología Pediátrica, Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Tenerife, España
2 shared publicationsAmel Haj Khelil
Fac Pharm, Lab Biochem & Mol Biol, Monastir, Tunisia
1 shared publication- Ana Fontalba
Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
1 shared publication - Ana Medeira
21Genética, Hospital Santa María, Lisboa, Portugal
1 shared publication
Latest Publications
- 1 February 2014
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 81 (02) , 142-145
Novel ATP6V0A4 mutation described in a Tunisian patient with distal renal tubular acidosis
Few data regarding molecular diagnosis of primary distal renal tubular acidosis (DRTA) in Tunisian population are available. Case report: 25-day-old male patient from consanguineous parents of Tunisian origin diagnosed with DRTA and without hearing impairment observed later in life. ATP6V0A4 gene sequencing demonstrated a novel homozygous G deletion in exon 13 (c.1221delG, p.Met408CysfsX10), leading to a premature stop codon. Conclusion: A novel ATP6V0A4 gene mutation confirmed autosomal recessive DRTA with normal hearing in the patient. Molecular analysis may help to rapidly diagnose autosomal recessive DRTA in Tunisian population.
- 1 February 2014
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 81 (02) , 142-145
Novel ATP6V0A4 mutation described in a Tunisian patient with distal renal tubular acidosis
Few data regarding molecular diagnosis of primary distal renal tubular acidosis (DRTA) in Tunisian population are available. Case report: 25-day-old male patient from consanguineous parents of Tunisian origin diagnosed with DRTA and without hearing impairment observed later in life. ATP6V0A4 gene sequencing demonstrated a novel homozygous G deletion in exon 13 (c.1221delG, p.Met408CysfsX10), leading to a premature stop codon. Conclusion: A novel ATP6V0A4 gene mutation confirmed autosomal recessive DRTA with normal hearing in the patient. Molecular analysis may help to rapidly diagnose autosomal recessive DRTA in Tunisian population.
- 1 January 2013
- Vol. 33 (33) , 27-45
Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso
Trobareu una actualització (2015) d'aquest document a: http://hdl.handle.net/2445/99427Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the underlying lesions are mediated by systemic thrombotic microangiopathy (TMA). Atypical HUS (aHUS) is a sub-type of HUS in which the TMA phenomena are the consequence of decreased regulation of the alternative complement pathway on cell surfaces due to a genetic cause. aHUS is an extremely rare disease that, despite the administration of standard treatment with plasma therapy, often progresses to terminal chronic renal failure with a high associated rate of mortality. In recent years, research has established the key role that the complement system plays in the induction of endothelial damage in patients with aHUS, through the characterisation of multiple mutations and polymorphisms in the genes that code for certain complement factors. Eculizumab is a monoclonal antibody that inhibits the terminal fraction of the complement protein, blocking the formation of a cell membrane attack complex. In prospective studies in patients with aHUS, administering eculizumab produces a rapid and sustained interruption in the TMA process, with significant improvements in long-term renal function and an important decrease in the need for dialysis or plasma therapy. In this document, we review and bring up to date the important aspects of this disease, with special emphasis on how recent advancements in diagnostic and therapeutic processes can modify the treatment of patients with aHUS
- 1 January 2013
- Vol. 33 (33) , 27-45
Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso
Trobareu una actualització (2015) d'aquest document a: http://hdl.handle.net/2445/99427Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the underlying lesions are mediated by systemic thrombotic microangiopathy (TMA). Atypical HUS (aHUS) is a sub-type of HUS in which the TMA phenomena are the consequence of decreased regulation of the alternative complement pathway on cell surfaces due to a genetic cause. aHUS is an extremely rare disease that, despite the administration of standard treatment with plasma therapy, often progresses to terminal chronic renal failure with a high associated rate of mortality. In recent years, research has established the key role that the complement system plays in the induction of endothelial damage in patients with aHUS, through the characterisation of multiple mutations and polymorphisms in the genes that code for certain complement factors. Eculizumab is a monoclonal antibody that inhibits the terminal fraction of the complement protein, blocking the formation of a cell membrane attack complex. In prospective studies in patients with aHUS, administering eculizumab produces a rapid and sustained interruption in the TMA process, with significant improvements in long-term renal function and an important decrease in the need for dialysis or plasma therapy. In this document, we review and bring up to date the important aspects of this disease, with special emphasis on how recent advancements in diagnostic and therapeutic processes can modify the treatment of patients with aHUS
- 1 May 2012
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 59 (5) , 707-710
Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome in Infants
- 1 May 2012
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 59 (5) , 707-710
Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome in Infants
- Open Access
- 8 September 2011
- Published by Springer Nature in BMC Medical Genetics
- Vol. 12 (1) , 116
Genetic diagnosis of X-linked dominant hypophosphatemic rickets in a cohort study: Tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type
Background: Genetic Hypophosphatemic Rickets (HR) is a group of diseases characterized by renal phosphate wasting with inappropriately low or normal 1,25-dihydroxyvitamin D3 (1,25(OH)2D) serum levels. The most common form of HR is X-linked dominant HR (XLHR) which is caused by inactivating mutations in the PHEX gene. The purpose of this study was to perform genetic diagnosis in a cohort of patients with clinical diagnosis of HR, to perform genotype-phenotype correlations of those patients and to compare our data with other HR cohort studies. Methods: Forty three affected individuals from 36 non related families were analyzed. For the genetic analysis, the PHEX gene was sequenced in all of the patients and in 13 cases the study was complemented by mRNA sequencing and Multiple Ligation Probe Assay. For the genotype-phenotype correlation study, the clinical and biochemical phenotype of the patients was compared with the type of mutation, which was grouped into clearly deleterious or likely causative, using the Mann-Whitney and Fisher's exact test. Results: Mutations in the PHEX gene were identified in all the patients thus confirming an XLHR. Thirty four different mutations were found distributed throughout the gene with higher density at the 3' end. The majority of the mutations were novel (69.4%), most of them resulted in a truncated PHEX protein (83.3%) and were family specific (88.9%). Tubular reabsorption of phosphate (TRP) and 1,25(OH)2D serum levels were significantly lower in patients carrying clearly deleterious mutations than in patients carrying likely causative ones (61.39 ± 19.76 vs. 80.14 ± 8.80%, p = 0.028 and 40.93 ± 30.73 vs. 78.46 ± 36.27 pg/ml, p = 0.013). Conclusions: PHEX gene mutations were found in all the HR cases analyzed, which was in contrast with other cohort studies. Patients with clearly deleterious PHEX mutations had lower TRP and 1,25(OH)2D levels suggesting that the PHEX type of mutation might predict the XLHR phenotype severity.
- 8 September 2011
- Published by Springer Nature in BMC Medical Genetics
- Vol. 12 (1) , 116
Open AccessGenetic diagnosis of X-linked dominant hypophosphatemic rickets in a cohort study: Tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type
Background: Genetic Hypophosphatemic Rickets (HR) is a group of diseases characterized by renal phosphate wasting with inappropriately low or normal 1,25-dihydroxyvitamin D3 (1,25(OH)2D) serum levels. The most common form of HR is X-linked dominant HR (XLHR) which is caused by inactivating mutations in the PHEX gene. The purpose of this study was to perform genetic diagnosis in a cohort of patients with clinical diagnosis of HR, to perform genotype-phenotype correlations of those patients and to compare our data with other HR cohort studies. Methods: Forty three affected individuals from 36 non related families were analyzed. For the genetic analysis, the PHEX gene was sequenced in all of the patients and in 13 cases the study was complemented by mRNA sequencing and Multiple Ligation Probe Assay. For the genotype-phenotype correlation study, the clinical and biochemical phenotype of the patients was compared with the type of mutation, which was grouped into clearly deleterious or likely causative, using the Mann-Whitney and Fisher's exact test. Results: Mutations in the PHEX gene were identified in all the patients thus confirming an XLHR. Thirty four different mutations were found distributed throughout the gene with higher density at the 3' end. The majority of the mutations were novel (69.4%), most of them resulted in a truncated PHEX protein (83.3%) and were family specific (88.9%). Tubular reabsorption of phosphate (TRP) and 1,25(OH)2D serum levels were significantly lower in patients carrying clearly deleterious mutations than in patients carrying likely causative ones (61.39 ± 19.76 vs. 80.14 ± 8.80%, p = 0.028 and 40.93 ± 30.73 vs. 78.46 ± 36.27 pg/ml, p = 0.013). Conclusions: PHEX gene mutations were found in all the HR cases analyzed, which was in contrast with other cohort studies. Patients with clearly deleterious PHEX mutations had lower TRP and 1,25(OH)2D levels suggesting that the PHEX type of mutation might predict the XLHR phenotype severity.
- 31 March 2011
- Published by Elsevier in Diálisis y Trasplante
- Vol. 32 (1) , 46-48
Profesor Juan Rodríguez Soriano (1933-2010)
- 31 March 2011
- Published by Elsevier in Diálisis y Trasplante
- Vol. 32 (1) , 46-48
Profesor Juan Rodríguez Soriano (1933-2010)
- 22 February 2011
- Published by Springer Nature in Pediatric Nephrology
- Vol. 26 (5) , 823-825
In memoriam: Professor Juan Rodríguez Soriano (1933–2010)
- 22 February 2011
- Published by Springer Nature in Pediatric Nephrology
- Vol. 26 (5) , 823-825
In memoriam: Professor Juan Rodríguez Soriano (1933–2010)
- 10 November 2010
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 170 (1) , 15-20
Clinical practice
Proteinuria detection in children is a challenge. Five percent to 15% and 0.4–1% of school children present either transient (benign) or persistent increased amount of protein in urine, respectively. Persistent proteinuria constitutes not only a sign of overt kidney disease but may also be the first indicator of silent renal damage. Proteinuria is a marker for hyperfiltration in individuals with reduced nephron mass and one of the most important independent risk factor for renal disease progression as well. It constitutes the single most important risk factor for future loss of kidney function, preceding glomerular filtration rate reduction. Further, proteinuria itself is diagnostic of cardiovascular disease with prognostic value and target organ involvement in high-risk populations such as diabetic, obese, hypertensive children, or those with known reduced renal mass or previous renal injury. Current strategies to prevent CKD progression, a concept known as renoprotection, are focused on reducing urinary protein excretion among other factors. Reversibility of organ damage in early stages is possible; therefore, pediatricians should screen children for proteinuria or microalbuminuria, mainly in high-risk groups.
- 10 November 2010
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 170 (1) , 15-20
Clinical practice
Proteinuria detection in children is a challenge. Five percent to 15% and 0.4–1% of school children present either transient (benign) or persistent increased amount of protein in urine, respectively. Persistent proteinuria constitutes not only a sign of overt kidney disease but may also be the first indicator of silent renal damage. Proteinuria is a marker for hyperfiltration in individuals with reduced nephron mass and one of the most important independent risk factor for renal disease progression as well. It constitutes the single most important risk factor for future loss of kidney function, preceding glomerular filtration rate reduction. Further, proteinuria itself is diagnostic of cardiovascular disease with prognostic value and target organ involvement in high-risk populations such as diabetic, obese, hypertensive children, or those with known reduced renal mass or previous renal injury. Current strategies to prevent CKD progression, a concept known as renoprotection, are focused on reducing urinary protein excretion among other factors. Reversibility of organ damage in early stages is possible; therefore, pediatricians should screen children for proteinuria or microalbuminuria, mainly in high-risk groups.
- 1 October 2009
- Published by Springer Nature in Pediatric Nephrology
- Vol. 24 (10) , 2047-2050
Growth failure associated with sirolimus: case report
An 11-year-old girl, who was a renal transplant recipient, developed linear growth failure associated in time with sirolimus (SRL) treatment. After 5 years of functional graft [creatinine clearance (CCr) 90 ml/min per 1.73 m2 body surface area], she developed acute renal failure due to calcineurin inhibitor-related hemolytic uremic syndrome, and cyclosporine A was replaced by SRL. Before the drug change, she had been growing normally (5.5 cm/year) and had reached the 33.9 percentile (P) of height (z-height −0.41), similar to her target. Two years later, her height had decreased to P 6th (z-height −1.54), as her growth velocity had diminished to 2.2 cm/year, despite optimal renal function (CCr 68 ml/min per 1.73 m2). Human recombinant growth hormone was needed to promote her catch-up growth and achieve the P 49th of height (z-height −0.03). SRL may have deleterious effects on growing children due its characteristic anti-proliferative and anti-angiogenic properties. Pediatric transplant recipients’ linear growth should be cautiously monitored while they are being given SRL.
- 1 October 2009
- Published by Springer Nature in Pediatric Nephrology
- Vol. 24 (10) , 2047-2050
Growth failure associated with sirolimus: case report
An 11-year-old girl, who was a renal transplant recipient, developed linear growth failure associated in time with sirolimus (SRL) treatment. After 5 years of functional graft [creatinine clearance (CCr) 90 ml/min per 1.73 m2 body surface area], she developed acute renal failure due to calcineurin inhibitor-related hemolytic uremic syndrome, and cyclosporine A was replaced by SRL. Before the drug change, she had been growing normally (5.5 cm/year) and had reached the 33.9 percentile (P) of height (z-height −0.41), similar to her target. Two years later, her height had decreased to P 6th (z-height −1.54), as her growth velocity had diminished to 2.2 cm/year, despite optimal renal function (CCr 68 ml/min per 1.73 m2). Human recombinant growth hormone was needed to promote her catch-up growth and achieve the P 49th of height (z-height −0.03). SRL may have deleterious effects on growing children due its characteristic anti-proliferative and anti-angiogenic properties. Pediatric transplant recipients’ linear growth should be cautiously monitored while they are being given SRL.
- 1 January 2001
- Published by Elsevier in Medicina Clinica
- Vol. 116 (10) , 361-364
Pronóstico en la vida adulta de la nefropatía igA diagnosticada en la edad pediátrica
- 1 January 2001
- Published by Elsevier in Medicina Clinica
- Vol. 116 (10) , 361-364
Pronóstico en la vida adulta de la nefropatía igA diagnosticada en la edad pediátrica